Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnanda Developments Plc Regulatory News (ANA.PL)

Share Price Information for Ananda Developments Plc (ANA.PL)

Aquis Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.315
Bid: 0.28
Ask: 0.35
Change: 0.00 (0.00%)
Spread: 0.07 (25.00%)
Open: 0.315
High: 0.315
Low: 0.315
Prev. Close: 0.315
ANA.PL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ananda Launches New Interactive Investor Hub

14 Dec 2023 07:00

RNS Number : 6859W
Ananda Developments PLC
14 December 2023
 

 

Reach - Non-Regulatory

 

Ananda Developments plc

 ("Ananda" or the "Company")

 

Ananda Developments Launches New Interactive Investor Hub, investors.anandadevelopments.com to provide stakeholders with a more proactive method of communication and enquiry support

 

Ananda Developments Plc ('Ananda') a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions is pleased to announce the launch of Ananda's Interactive Investor Hub. For both existing and prospective stakeholders it brings all Ananda's content into a single integrated platform to better inform and engage with investors and stakeholders, including:

 

? regulatory announcements

? annual and interim reports

? corporate presentations

? educational material

? Interviews with the company's directors

? corporate research on Ananda Developments

 

Investor Hub also provides an interactive online experience allowing the Company's stakeholders to comment on and ask the Ananda team questions via a portal which will be monitored and responded to promptly. Company RNSs will also still be released via the current regulated services.

 

To sign up for the Ananda Investor Hub:

 

1. Visit investors.anandadevelopments.com

2. Follow the prompts to sign up for an investor hub account

3. Complete your account profile

 

Ananda's CEO, Melissa Sturgess commented: "We have always encouraged our stakeholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our stakeholders including shareholders, potential shareholders and interested parties to interact with Ananda. Investor Hub will also allow us to share more video material, information and insights about our activities and plans. We encourage our shareholders, potential shareholders and wider stakeholders to trial Investor Hub and provide feedback."

 

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:

· Investor Hub: investors.anandadevelopments.com

· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y= 

· LinkedIn: https://www.linkedin.com/company/anadevelopments/ 

· Twitter: https://twitter.com/AnandaPlc

· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For more information please contact:

InvestorHub

Engage with us directly at Ananda Developments Investor Hub

Sign up at investors.anandadevelopments.com

ANANDA DEVELOPMENTS PLC

Chief Executive Officer

Melissa Sturgess

Executive Director

Jeremy Sturgess-Smith

+44 (0)7463 686 497 ir@anandadevelopments.com

SP ANGEL CORPORATE FINANCE LLP

+44 (0)20 3470 0470

Corporate Finance

Richard Morrison

Harry Davies-Ball

 

Corporate Broking

Abigail Wayne

Rob Rees

 

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based

medicines for the treatment of complex, chronic inflammatory pain conditions.

 

For further information on the Company visit https://anandadevelopments.com/ or sign up at www.investors.anandadevelopments.com.

https://investors.anandadevelopments.com/link/lya2je

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFUFLDEDSELE
Date   Source Headline
2nd May 202412:00 pmRNSResponse to FSA-FSS Cannabidiol Safety Assessment
21st Mar 20247:00 amRNSEstablishment of Scientific Advisory Board
28th Feb 20247:00 amRNSEndometriosis Trial Drug Supply Agreement Signed
26th Feb 202412:00 pmRNSAnanda presenting at Master Investor Show
26th Feb 20247:00 amRNSQuarterly Trading Statement to 31 January 2024
6th Feb 20247:00 amRNSAppointment of Adviser
23rd Jan 20247:00 amRNSAppointment of Scientific Advisers
14th Dec 20237:00 amRNSAnanda Launches New Interactive Investor Hub
29th Nov 20232:39 pmRNSQuarterly Trading Statement to 31 October 2023
14th Nov 20237:00 amRNSDrug Supply Agreement Signed
8th Nov 20237:30 amRNSInvestor Presentation via Investor Meet Company
8th Nov 20237:00 amRNSTHC Oil Patent Application Filed
1st Nov 20237:00 amRNSMOU signed with Nottingham Trent University
24th Oct 20232:20 pmRNSInterim Results to 31 July 2023
6th Sep 20237:00 amRNSIssue of Convertible Loan Notes
31st Aug 20237:00 amRNSShareholder Update
25th Aug 202312:01 pmRNSResearch Roundup
24th Aug 20232:28 pmRNSResult of AGM
15th Aug 20237:00 amRNSNHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL
31st Jul 20235:44 pmRNSCompletion of Audit & Notice of AGM
27th Jul 20237:00 amRNSFirst Cannabinoid Medicines Launched
13th Jul 202310:22 amRNSUnaudited Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.